Infertility Research LRP (CIR–LRP) is authorized by section 487B of the PHS Act (42 U.S.C. 288–2), and the Health Disparities Research LRP (HD–LRP) is authorized by section 485G (42 U.S.C. 287c–33).

The Loan Repayment Programs can repay up to $35,000 per year toward a participant’s extant eligible educational loans, directly to financial institutions. The information proposed for collection will be used by the Division of Loan Repayment to determine an applicant’s eligibility for participation in the program. Frequency of Response: Initial application and one- or two-year renewal application. Affected Public: Individuals or households, nonprofits, and businesses or other for-profit. Type of Respondents: Physicians, other scientific or medical personnel, and institutional representatives. The annual reporting burden is as follows:

<table>
<thead>
<tr>
<th>Type of respondents</th>
<th>Number of respondents</th>
<th>Estimated number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Annual burden hours requested</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intramural LRPs:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial Applicants</td>
<td>50</td>
<td>1</td>
<td>10.11</td>
<td>505.50</td>
</tr>
<tr>
<td>Advisors/Supervisors</td>
<td>50</td>
<td>1</td>
<td>1.1</td>
<td>50.00</td>
</tr>
<tr>
<td>Recommenders</td>
<td>140</td>
<td>1</td>
<td>.5</td>
<td>70.00</td>
</tr>
<tr>
<td>Financial Institutions</td>
<td>10</td>
<td>1</td>
<td>.25</td>
<td>2.50</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>250</td>
<td></td>
<td></td>
<td>628.00</td>
</tr>
<tr>
<td><strong>Extramural LRPs:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial Applicants</td>
<td>2,050</td>
<td>1</td>
<td>10.75</td>
<td>22,037.50</td>
</tr>
<tr>
<td>Advisors/Supervisors</td>
<td>1,840</td>
<td>1</td>
<td>1</td>
<td>1,840.00</td>
</tr>
<tr>
<td>Recommenders</td>
<td>6,150</td>
<td>1</td>
<td>.5</td>
<td>3,075.00</td>
</tr>
<tr>
<td>Financial Institutions</td>
<td>100</td>
<td>1</td>
<td>.25</td>
<td>25.00</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>10,140</td>
<td></td>
<td></td>
<td>26,977.50</td>
</tr>
<tr>
<td><strong>Intramural LRPs:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renewal Applicants</td>
<td>50</td>
<td>1</td>
<td>7.42</td>
<td>371.00</td>
</tr>
<tr>
<td>Advisors/Supervisors</td>
<td>50</td>
<td>1</td>
<td>2.2</td>
<td>110.00</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>100</td>
<td></td>
<td></td>
<td>481.00</td>
</tr>
<tr>
<td><strong>Extramural LRPS:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renewal Applicants</td>
<td>1,200</td>
<td>1</td>
<td>8.58</td>
<td>10,296.00</td>
</tr>
<tr>
<td>Advisors/Supervisors</td>
<td>900</td>
<td>1</td>
<td>1.7</td>
<td>1,530.00</td>
</tr>
<tr>
<td>Recommenders</td>
<td>3,500</td>
<td>1</td>
<td>.5</td>
<td>1,750.00</td>
</tr>
<tr>
<td><strong>Subtotal</strong></td>
<td>5,600</td>
<td></td>
<td></td>
<td>13,576.00</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>16,090</td>
<td></td>
<td></td>
<td>41,662.50</td>
</tr>
</tbody>
</table>

The annualized cost to respondents is estimated at $1,701,641.69. The annualized cost to the Federal Government for administering the Loan Repayment Programs is expected to be $1,448,100. This cost includes administrative support by the Division of Loan Repayment and $800,000 for the continuing development and maintenance of the LRP Management Information System/Online Application System (MIS/OAS).

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Milton Hernandez, PhD, Director, Division of Loan Repayment, National Institutes of Health, 6011 Executive Blvd., Room 206 (MSC 7650), Bethesda, Maryland 20892–7650. Dr. Hernandez may be contacted via e-mail at mh35c@nih.gov or by calling 301–496–0180. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: February 4, 2011.

Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2011–2995 Filed 2–9–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials,
and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multiplexed Sensitive Testing for Drugs of Abuse (2220).

Date: February 15, 2011.
Time: 1:30 p.m. to 5 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892–9550, (301) 435–1439, f33ec@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: February 4, 2011.

Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–2988 Filed 2–9–11; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Vascular Biology.

Date: February 16–17, 2011.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Larry Pinkus, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4132, MSC 7802, Bethesda, MD 20892, (301) 435–1214, pinkusl@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Clinical and Integrative Cardiovascular Sciences.

Date: February 16, 2011.
Time: 12 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Olga A. Tjurmina, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7814, Bethesda, MD 20892, (301) 451–1375, ot3d@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute of Environmental Health Sciences; Notice of Meetings

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Interagency Breast Cancer and Environmental Research Coordinating Committee Research Translation, Dissemination, and Policy Implications Subcommittee.

These meetings will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance or reasonable accommodations, should inform the Contact Person listed below at least 10 days in advance of the meeting.

Name of Committee: Interagency Breast Cancer and Environmental Research Coordinating Committee (IBCERC) Research Translation, Dissemination, and Policy Implications Subcommittee.

Date: March 16, 2011.
Time: 1 p.m. to 4 p.m.
Agenda: The purpose of the meeting is to continue the work of the Research Translation, Dissemination, and Policy Implications Subcommittee as it addresses a broad set of objectives related to the overall mandate of the IBCERC including: increasing public participation in decisions relating to breast cancer research by increasing the involvement of patient advocacy and community organizations representing a broad geographical area and creating models for dissemination of information regarding the progress of breast cancer research. The meeting agenda will be available on the Web at http://www.niehs.nih.gov/about/ogstructure/boards/ibcerc/.

Place: Conference Call: This meeting will be conducted remotely, via conference call. To attend the meeting, please RSVP via e-mail to ibcerc@niehs.nih.gov at least 10 days in advance and instructions for joining the meeting will be provided.

Contact Person: Gwen W. Collman, PhD, Director, Division of Extramural Research and Training, National Institute of Environmental Health Sciences, 615 Davis Dr., KEY615/3112, Research Triangle Park, NC 27709, (919) 541–4980, collman@niehs.nih.gov.

Name of Committee: Interagency Breast Cancer and Environmental Research Coordinating Committee (IBCERC) Research Translation, Dissemination, and Policy Implications Subcommittee.

Date: April 15, 2011.
Time: 1 p.m. to 4 p.m.
Agenda: The purpose of the meeting is to continue the work of the Research Translation, Dissemination, and Policy Implications Subcommittee as it addresses a broad set of objectives related to the overall mandate of the IBCERC including: increasing